BioAge Labs, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.bioagelabs.com
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared With Tirzepatide Alone in Participants With Obesity Aged 55 Years and Over
Phase 2
Suspended
- Conditions
- Obesity
- Interventions
- Drug: Oral Azelaprag (BGE-105)Drug: Oral Placebo for Azelaprag (BGE-105)Drug: Tirzepatide PlaceboDrug: Tirzepatide
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- BioAge Labs, Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT06515418
- Locations
- 🇺🇸
Site 110, Mesa, Arizona, United States
🇺🇸Site 107, Los Angeles, California, United States
🇺🇸Site 103, Montclair, California, United States
Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer Study
- Interventions
- Drug: Azelaprag
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- BioAge Labs, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06141889
- Locations
- 🇳🇿
New Zealand Clinical Research, Auckland, New Zealand
Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery
Phase 2
Withdrawn
- Conditions
- Acute Posthemorrhagic Anemia
- Interventions
- Drug: BGE-117, 4mgDietary Supplement: Ferrous SulfateOther: Matching PlaceboDrug: BGE-117, 12mg
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- BioAge Labs, Inc.
- Registration Number
- NCT05152641
- Locations
- 🇦🇺
Renal Research, Gosford, New South Wales, Australia
Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging
Phase 2
Withdrawn
- Conditions
- Anemia
- Interventions
- Drug: BGE-117Other: Placebo
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- BioAge Labs, Inc.
- Registration Number
- NCT04815603
- Locations
- 🇦🇺
Emeritus Research Sydney, Botany, New South Wales, Australia
🇦🇺Browns Plains Family (Sonic/IPN), Browns Plains, Queensland, Australia
🇦🇺Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
Phase 2
Terminated
- Conditions
- Covid19
- Interventions
- Drug: BGE-175Other: Placebo
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- BioAge Labs, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT04705597
- Locations
- 🇧🇷
Conjunto Hospitalar de Mandaqui, São Paulo, Sao Paulo, Brazil
🇺🇸UCI Center for Clinical Research, Orange, California, United States
🇧🇷Hospital Felicio Rocho (HFR), Belo Horizonte, Minas Gerais, Brazil
© Copyright 2025. All Rights Reserved by MedPath